References
- Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103.
- National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal National Institute for Health and Care Excellence. 2013. [cited 2019 Mar 11]. Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781.
- Zuluaga-Sanchez S, Hess LM, Wolowacz SE, et al. Cost-effectiveness of olaratumab in combination with doxorubicin for patients with soft tissue sarcoma in the United States. Sarcoma. 2018;2018:1.
- Graham C, Knox H, Hess LM, et al. Cost-effectiveness in the second-line treatment of non-small cell lung cancer (NSCLC) in the US. Value Health. 2015;18(7):A457–A458.
- Kumar G, Woods B, Hess LM, et al. Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the US. Lung Cancer. 2015;89(3):294–300.
- Wen F, Zheng H, Zhang P, et al. OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer. BMJ Open. 2018;8(4):e020128.
- Huang M, Lou Y, Pellissier J, et al. Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States. J Med Econ. 2017;20(2):140–150.
- Hess LM, Rajan N, Winfree K, et al. Cost analyses in the US and Japan: a cross-country comparative analysis applied to the PRONOUNCE trial in non-squamous non-small cell lung cancer. Adv Ther. 2015;32(12):1248–1262.
- Lewis G, Peake M, Aultman R, et al. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom. J Int Med Res. 2010;38(1):9–21.
- US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. November 27, 2017. [cited 2019 Apr 18]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.
- Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13(3):247–255.
- Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–673.
- Zinner RG, Obasaju CK, Spigel DR, et al. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients with advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015;10(1):134–142.
- Senan S, Brade A, Wang LH, et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. JCO. 2016;34(9):953–962.
- Bureau of Labor Statistics (BLS). Inflation & prices: medical care services in U.S. city average, all urban consumers, not seasonally adjusted. 2017. [cited 2017 Oct 12]. Available from: https://www.bls.gov/data/.
- Red Book Online [database on the Internet]. Ann Arbor, MI: Truven Health Analytics; 2017. [cited 2017 Dec 20]. Available from: http://www.micromedexsolutions.com/. Subscription required to view.
- HCUPnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality, Rockville, MD. [cited 2018 Feb 20]. Available from: https://hcupnet.ahrq.gov/.
- Centers for Disease Control and Prevention (CDC). Health, United States, with special feature on emergency care (Data table for Figure 29), 2012. [cited 2017 Dec 27]. Available from: http://www.cdc.gov/nchs/data/hus/hus12.pdf.
- Centers for Medicare & Medicaid Services (CMS). Physician fee schedule. 2017. [cited 2017 Dec 27]. Available from: https://www.cms.gov/apps/physician-fee-schedule/overview.aspx.
- Centers for Medicare & Medicaid Services (CMS). Addendum B. 2018a. [cited 2017 Dec 27]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Addendum-A-and-Addendum-B-Updates.html?DLSort=2&DLEntries=10&DLPage=1&DLSortDir=descending.
- Centers for Medicare and Medicaid Services (CMS). Clinical Laboratory Fee Schedule. 2018b. v1. [cited 2017 Dec 28]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Clinical-Laboratory-Fee-Schedule-Files.html.
- ICH E3. Guideline for Industry: Structure and Content of Clinical Study Reports. 1996. [cited 2018 Nov 19]. Available from: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073113.pdf.